Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind placebo-controlled dose-escalation study of YA-101 in multiple system atrophy
jRCT2031250249Phase 2Active, not recruiting
- Sponsor
- Dasher Neuroscience
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing YA-101 BID with Placebo BID (2 arms). Primary endpoint: Adverse events. Started Aug 2025; status: active, not recruiting.
02
Drugs
YA-101
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2031250249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250249.